Submitted Successfully!
To reward your contribution, here is a gift for you: A free trial for our video production service.
Thank you for your contribution! You can also upload a video entry or images related to this topic.
Version Summary Created by Modification Content Size Created at Operation
1
mina Student ardestani
 -- 3066 2022-11-06 07:42:34 |
2 update references and layout
Rita Xu
 Meta information modification 3066 2022-11-07 03:07:42 |

Video Upload Options

Do you have a full video?
Send video materials Upload full video

Confirm

Are you sure to Delete?
Yes No
Cite
If you have any further questions, please contact Encyclopedia Editorial Office.
Ardestani, M.;  Khorsandi, Z.;  Keshavarzipour, F.;  Iravani, S.;  Sadeghi-Aliabadi, H.;  Varma, R.S. Heterocyclic Compounds as Hsp90 Inhibitors. Encyclopedia. Available online: https://encyclopedia.pub/entry/33140 (accessed on 17 September 2024).
Ardestani M,  Khorsandi Z,  Keshavarzipour F,  Iravani S,  Sadeghi-Aliabadi H,  Varma RS. Heterocyclic Compounds as Hsp90 Inhibitors. Encyclopedia. Available at: https://encyclopedia.pub/entry/33140. Accessed September 17, 2024.
Ardestani, Mina, Zahra Khorsandi, Fariba Keshavarzipour, Siavash Iravani, Hojjat Sadeghi-Aliabadi, Rajender S. Varma. "Heterocyclic Compounds as Hsp90 Inhibitors" Encyclopedia, https://encyclopedia.pub/entry/33140 (accessed September 17, 2024).
Ardestani, M.,  Khorsandi, Z.,  Keshavarzipour, F.,  Iravani, S.,  Sadeghi-Aliabadi, H., & Varma, R.S. (2022, November 06). Heterocyclic Compounds as Hsp90 Inhibitors. In Encyclopedia. https://encyclopedia.pub/entry/33140
Ardestani, Mina, et al. "Heterocyclic Compounds as Hsp90 Inhibitors." Encyclopedia. Web. 06 November, 2022.
Heterocyclic Compounds as Hsp90 Inhibitors
Edit
This entry is adapted from the peer-reviewed paper 10.3390/pharmaceutics14102220

Heat shock proteins (Hsps) have garnered special attention in cancer therapy as molecular chaperones with regulatory/mediatory effects on folding, maintenance/stability, maturation, and conformation of proteins as well as their effects on prevention of protein aggregation. Hsp90 ensures the stability of various client proteins needed for the growth of cells or the survival of tumor cells; therefore, they are overexpressed in tumor cells and play key roles in carcinogenesis. Accordingly, Hsp90 inhibitors are recognized as attractive therapeutic agents for investigations pertaining to tumor suppression. Natural Hsp90 inhibitors comprising geldanamycin (GM), reclaimed analogs of GM including 17-AAG and DMAG, and radicicol, a natural macrocyclic antifungal, are among the first potent Hsp90 inhibitors.

Hsp90 inhibitor co-chaperone heterocycle molecules

1. Introduction

Cancer refers to a variety of diseases caused by escalating uninhibited cell proliferation, which may spread beyond tissue range. Cancer is initiated with the deformation of a normal cell caused by several hereditary factors, lifestyle, immune system defects, environmental/occupational factors, possible toxicity from medications, including the aging process, causing damage or genetic mutations [1][2][3][4]. The mechanisms of control, proliferation, and differentiation of cells are disrupted [5][6][7][8][9], which leads to deviation of normal cells from their regular growth path [10][11][12]. Tumor cells may acquire autonomy in two ways, namely activation of a growth-promoting oncogene or inactivation of a growth-inhibiting gene [13][14][15]. Cancer is one of the major death reasons which ranked after cardiovascular diseases; therefore, anticancer explorations have attracted much attention, especially through the evaluation of the deactivation of various proteins, such as tubulin, aromatase, and heat shock proteins [16][17][18][19][20][21][22][23][24].
Heat shock proteins (Hsps) inhibitors are one of the most eminent active anticancer agents with appropriate effects on several strange signaling paths in tumors; notably, these inhibitors can help to surmount several notorious problems regarding resistance cancers. Hsps act as proteins for vital cellular activities, including protein accumulation, secretion, and regulation of gene expression through direct correlation with transcription factors; the cellular expression is increased due to various stressors. Hsps are classified by their molecular weight into the Hsp110, Hsp90, Hsp70, Hsp60, Hsp40, and Hsp27; most of them being generally characterized as ATP-dependent [25][26][27]. Additionally, Hsp90 can regulate the activity and stability of different client proteins with a wide range of sizes and functions as these client proteins have critical roles in proliferation, survival, protein misfolding, aggregation, and apoptosis. There are four various homologs of Hsp90: cytosolic Hsp90 (including Hsp90α, Hsp90β), TRAP1 (tumor necrosis factor receptor-associated protein 1) in mitochondrial, GRP94 (94 kDa glucose-regulated protein) in the endoplasmic reticulum (ER), and Hsp90C in chloroplasts [27].
The crystal formation of Hsp90 was first defined in 1996 as a homodimer with a three-part monomer. The N-terminal domain (~35-kDa) is fabricated from layers of a/b sandwich structures formed in the pocket, acting as a binding site for adenine nucleotides. The requirement of ATP in Hsp90 is associated with auto-phosphorylation with the N-terminal folding pattern; the superfamily of ATPase has shown similar activity to Hsp90 by type II topoisomerases and MutL (Mutator L) [28][29].
A client protein binding site and nuclear localization signal, Hsp90 middle domain (~35 kDa), entails precise identification of client proteins and molecular regulator chaperones to activate the appropriate substrate, such as ATP hydrolysis [30]. The C-terminal domain (~12 kDa) is the site of dimerization close to the ATP binding site and a pentapeptide domain (Met-Glu-Glu-Val-Asp or MEEVD), as well as the binding site of co-chaperones of Hsp90 consisting of Sti15 and Hop [31]; the Hsp90 ATPase cycle is depicted in Figure 1.
Pharmaceutics 14 02220 g001
Figure 1. ATPase cycle in Hsp90.
Hsp90 consists of a chaperoning subsidiary with the assistance of co-chaperones and ATP. Initially, the client protein attaches to the M domain with the co-chaperones source; afterward, the ATP binds to the N domain to dimer the Hsp90, leading to the production of “closed form” protein. The client protein is reformed, while the required energy is supplied from the bond division process, and ATP is hydrolyzed to ADP and unfastened phosphate. The release of client proteins and ADP from the complex occurs after covering the chaperoning function; ATP binds to the N terminal via a standard chaperoning cycle and then the client protein binds to Hsp90 by assisting co-chaperones [32][33][34].
Due to the unique effectiveness of Hsp90 inhibitors in cancer therapy, researchers have focused on them in recent decades [35][36][37][38][39][40][41][42][43][44][45][46][47]. Hsp90 is responsible for the conformational maturation of 500 client protein substrates embracing transcription factors, receptors, kinases, or oncoproteins, which might be overexpressed and/or mutated in most cancers [48]. Consequently, the inhibition of Hsp90 is contemplated an attractive cancer-treating strategy due to its impacts on oncoprotein and pathways, concurrently [48][49].

2. Hsp90 Inhibitors

2.1. Natural Inhibitors

The first reported natural Hsp90 inhibitor has been a macrocyclic product called geldanamycin (1) (GM), extracted from the culture of Streptomyces hygroscopicus in 1970 which is known as an antibiotic compound (Scheme 1) [50]. Due to its unacceptable toxicological properties, the additional development of this compound was averted. However, the Hsp90 inhibitory activity of several geldanamycin analogs, namely, 17-dimethylaminoethylamino-17-demethoxygeldanamycin (17-DMAG), and 17-allylamino-17-demethoxygeldanamycin (17-AAG) are studied, but their clinical trials have been interrupted due to their poor solubility, complex formulation, and hepatotoxicity [51][52][53][54][55][56].
Pharmaceutics 14 02220 sch001
Scheme 1. Chemical structure of geldanamycin and its analogs.
One of the developed GM analogs is herbimycin A in which the methoxy substitution is located at positions C-11 and C-15, and the methoxy group is not present at position C-17; GM and herbimycin A (2) can induce Hsp70 expression in fibroblasts [57]. Macbecin I (3) as a GM analog has been developed with a similar structure to herbimycin A, except that the methoxy group at C-6 is replaced by a methyl group. Macbecin II (4) is a hydroquinone analog of macbecin I with less separation tendency due to its inferior structural instability [58][59]. The chemical structures of Herbimycin A and macbecin (I and II) are depicted in Scheme 2.
Pharmaceutics 14 02220 sch002
Scheme 2. Chemical structures of herbimycin A, macbecin I, and macbecin II.
IPI-504 (retaspimycin hydrochloride) (5) and IPI-493 (17-AG) (6) (Scheme 3) are more soluble analogs of GM and both of them inhibit Hsp90 activity through the degradation of client proteins. Several clinical trials (phase I and II) have been disclosed on different types of cancers including multiple myeloma, metastatic gastrointestinal stromal tumor (GIST), refractory non-small cell lung cancer (NSCLC), and chronic myelogenous leukemia (CML) [60]. IPI-493, equivalent to 17-AAG, obstructs the growth of SKBr3 breast cancerous cells, which may be derived from a similar major metabolite. IPI-493 exhibited highly effective results in GIST xenografts carrying heterogeneous KIT mutations in a preclinical investigation; these findings led to the start of its phase I clinical trial studies [61][62][63].
Pharmaceutics 14 02220 sch003
Scheme 3. Chemical structures of IPI-504 and IPI-493.
Benzoquinone ansamycins are also known as Hsp90 inhibitors that act as anti-malarial, antiviral, and anti-surra agents, and their efficacy in the treatment of cardiac arrest, stroke, and Alzheimer’s has been explored [64]. One of the natural Hsp90 inhibitors is Radicicol (RD) (7), which has been isolated from Monosporium bonorden, it can link to the N-terminal ATP binding site. RD is a potential cell growth inhibitor, but its unstable metabolite in the body leads to inactivity; therefore, elaborative studies have been focused on the modification of its structures to obtain analogs with better stability [65].
KF25706 (8) and KF2711(9) have been introduced as more soluble analogs of RD with significant inhibition of the Hsp90 activity. As depicted in their chemical structure (Scheme 4), the carbonyl group in RD has been replaced with the oxime group, from the point of view of chemistry; this replacement can reduce its Michael acceptor electrophilicity thus improving the stability. However, their anticancer investigations have been limited to in vivo and animal model studies [65][66].
Pharmaceutics 14 02220 sch004
Scheme 4. Chemical structures of Radicicol, KF25706, and KF2711.

2.2. Synthetic Hsp90 Inhibitors

2.2.1. Purine-Based Structures

Naturally-derived Hsp90 inhibitors may suffer from some disadvantages, including low solubility and restricted activity. To overcome these limitations, the usage of synthesized Hsp90 inhibitors has garnered much attention; for instance, purine-scaffold-based compounds were reported as effective Hsp90 inhibitors with good solubility and an acceptable level of cell permeability [67]. Purine is an aromatic heterocycle compound consisting of two fused rings. Purine derivatives have exhibited significant pharmaceutical activities such as anticancer, anti-HIV-1, and antimicrobial properties [68][69][70][71][72]. Purine and pyrimidine-based entities are essential natural heterocyclic compounds that have a critical role in several metabolic and cellular conversion processes in deoxyguanosine monophosphate (DGMP) nucleotide (AMP). Moreover, the chemical structure of several biologically important molecules, such as ATP, GTP, cyclic AMP, NADH, and 3′-phosphoadenosine-5′-phosphosulfate (PAPS) contain fused purine ring. In chemical terms, purine is a nitrogen-rich heterocyclic compound comprising two rings of pyrimidine and imidazole, and because of the lack of natural sources, they ought to be prepared through synthetic organic reactions [73][74][75].
The activity of a purine-based molecule as a synthesized Hsp90 inhibitor (PU3) has been investigated by assessing its interaction in Hsp90 K ADP/ADP binding site. As a theoretical outcome, this molecule covered all the necessary interactions with hosting protein; the Lys112 interacted with methoxy groups, and the hydrophobic pocket was occupied (Figure 2) [76]. The purine derivatives PU3 and Pu24FCl (Scheme 5) have been introduced as potential small-molecule Hsp90 inhibitors through binding to the Hsp90 ADP/ATP site. The trimethoxy phenyl functional group of Pu24FCl makes it suitable to bind into the phosphate region of the host protein. Bao et al. reported a purine-based Hsp90 inhibitor with potential oral activity, named CUDC-305 (12), it is a unique compound due to its: ability to extremely privilege into the tissue of the brain, prolonged duration in intracranial tumors in animal models, and function in intracranial glioblastoma models; these attractive features may be raised from its fascinating high lipophilicity (clog P of 4.0) (Scheme 5) [77].
Pharmaceutics 14 02220 g002
Figure 2. Molecular docking analysis of PU3 in interaction with Hsp90.
Pharmaceutics 14 02220 sch005
Scheme 5. Chemical structures of PU3, PU24FCl, BIIB021, and CUDC-305.
A family of 8-arylsulfonyl analogs of PU3 (10) have been synthesized to evaluate the influence of the aryl part on inhibitory function and are being introduced as a purine-based Hsp90 inhibitor with selective activities which successfully enters clinical trials [78][79][80][81]. BIIB021 (11) has been the first fully synthetic Hsp90 inhibitor that moved in clinical trials endowed with its special properties that facilitated its formulation and bioavailability improvement; it binds to Hsp90 with high affinity and inhibits tumor growth. In phase I clinical trials, BIIB021 exhibited well-tolerated and good antitumor activity [82]. Therefore, this most developed purine-based compound, entered phase II clinical trials for GIST treatment. Pharmacokinetic parameters for BIIB021 600 mg, the mean Cmax was 1.5 µmol and the mean AUC was 2.9 µmol h; a Cmax > 1.5 µmol being associated with a decrease in standardized uptake value (SUVmax) [83].

2.2.2. Coumarin-Based Structures

Coumarin and its derivatives are important heterocyclic molecules endowed with various biological activities, such as platelet aggregation inhibition, antibacterial effects, and anticancer activity [84][85][86][87][88]. Novobiocin (13) is one of the first established organic compounds with a coumarin core that functioned as an Hsp90 inhibitor; it is a natural product with significant antibacterial DNA gyrase activity. However, its low efficiency in degrading Hsp90 clients (IC50 = ~700 µM) has discontinued more evaluations; therefore, research has mainly focused on structure-activity relationship (SAR) studies to identify other coumarin-based compounds with stronger inhibitor activity [89]. Modification of the 3-position of coumarin, from amide in novobiocin to urea, creates a new link to the hosting protein. The chemical structure of modified coumarin (14) is depicted in Scheme 6.
Pharmaceutics 14 02220 sch006
Scheme 6. Hsp90 inhibitors containing coumarin motif.
Among coumarin derivatives, compound 15 (Scheme 6) did not show any Hsp90 inhibitory activities, but additional investigations revealed its ability to interrupt MAPK signaling pathway by inhibiting the level of p-ERK and p-MEK; this function would be useful in anticancer activities [90]. Blagg et al. illustrated that the 4-hydroxyl and the 3′-carbamate functional groups of novobiocin have proven to be detrimental as their essential components for Hsp90 inhibitory activity by SAR studies. Therefore, indole moiety replacement in compound 16 significantly increased its activity (Scheme 6), more than 500 times that of novobiocin [91]. Furthermore, Shelton et al. synthesized KU135 as an Hsp90 inhibitor agent with anti-proliferative activity. The results showed that this compound can degrade Hsp90 client proteins through signaling pathways, a process that has stronger anti-proliferative effects than the N-terminal Hsp90 inhibitor 17-AAG. Notably, the explorations on this Hsp90 inhibitor demonstrated that this compound could inhibit G2/M cell cycle and have mitochondria-mediated apoptosis effects [92].
Garg et al, produced different analogs of ring-bound novobiocin (Scheme 7) wherein SAR and computational studies illustrated that when lactam was in α position, it produced more effective analogs than sugars. Activity of these derivatives was assessed as anti-proliferative agents against SKBr3 and MCF-7 cell lines. Among these derivatives, the cyclohexylamine analog demonstrated the best inhibitory effect with IC50 compared to bicycloalkyl and tricyclic amino analogs (0.35 μM against MCF-7 and 0.2 μM against SKBr3 cells) [93].
Pharmaceutics 14 02220 sch007
Scheme 7. Chemical structure of ring-bound novobiocin analogs synthesized and evaluated by Garg et al. [93].
Wei et al. reported some assorted coumarin compounds comprising the pyrazoline functional group, (compound 19 (a–f), Scheme 8) and evaluated their anticancer activity through several biological assays. Based on docking study results, all of these compounds are located in the active site of the N-terminus of Hsp90. Among these six derivatives, the structure of 19a exhibited higher binding energy and Hsp90 inhibitory function (IC50 = ~4.7 µM). All these derivatives reduced the viability of A549 lung cancerous cells, without any necrosis induction on them as they stimulated the apoptosis with blocking effects on the autophagic flux of HCP1 in A549 lung cancerous cells [94].
Pharmaceutics 14 02220 sch008
Scheme 8. Chemical structures of pyrazoline containing coumarin compounds, reported by Wei et al. [94].

2.2.3. Quinolone-Based Structures

Quinolines are one of the most important nitrogenous heterocyclic compounds that have been extensively examined due to their widespread pharmacology appliances, such as anti-malarial, antitumor, anti-parasitic, antibacterial, anti-asthma, antidiabetic, anti-inflammatory, antiplatelet, and antihypertensive activities [95][96][97][98][99][100][101][102]. Streptonigrin (isolated from Streptomyces flocculus) and lavendamycin have already been known as antimicrobial and antitumor compounds with quinoline skeleton (Scheme 9); they create efficient interactions with targets to act as a cancer chemotherapy agent and as Hsp90 inhibitors [103][104][105].
Pharmaceutics 14 02220 sch009
Scheme 9. Chemical structures of quinolones-based HSP90 inhibitors: Streptonigrin and Lavendamycin.
The chemical structures of synthesized quinolones-core organic compounds with Hsp90 inhibitory potentials properties have been investigated; their chemical structure is depicted in Scheme 10, named 22 to 32. Ganesh and co-workers reported the modest Hsp90 inhibitor activity of compound 22 (Scheme 10). Several quinoline-based organic compounds were synthesized and their activities were evaluated in micromolar concentrations using cell-based Western blot (WB) and fluorescent polarization (FP) techniques [106].
Pharmaceutics 14 02220 sch010
Scheme 10. Hsp90 inhibitors containing quinoline motif.
Studies of SAR, optimization of structures, and re-synthesis of several aminoquinoline compounds indicated their low Hsp90 inhibitor activity. However, the synthesized compound 23 (Scheme 10) exhibited high activity, with IC50 of ~0.73 µM and 1 µM in the low micro-molar range obtained in FP and WB assays, respectively. These compounds, with their simple chemical structures and facile synthesis pathways, are recognized as a series of new Hsp90 inhibitors [106]. Audisio and co-workers synthesized a novel array of 3-(N-substituted) aminoquinolin-2(1H)-one derivative and evaluated their anticancer activity using cell proliferation and flow cytometry, including biological assays.
Among these synthetic derivatives, compounds 24 and 25 (Scheme 10) offered the most effective inhibitory activity against various genes, such as Raf-1, HER2, CDK4, and estrogen receptors. It was indicated that compound 24 could stimulate apoptosis in MCF-7 breast cancer cells by activating caspases and subsequent division of poly (ADP-ribose) polymerase (PARP) and inhibiting the growth of all tumor cell-independent cell lines with growth inhibition of 50% (GI50) values in the range of 2 to 32 μM. The examined cell lines included MCF-7, T47D, IRGOV-1, Ishikawa, HT-29, Caco-2, and MDA-MB-231. In addition to these properties, only compound 24 was identified as mediated cell death inductor in a p23-independent procedure; the p23 was a small and important co-chaperone for the Hsp90 chaperoning pathway [107].
A series of 2-aroylquinoline-5,8-diones have been synthesized and their potential biological activities have been evaluated by Nepali and coworkers [108]. Among these Hsp90 inhibitors, compounds 26 and 27 could inhibit the growth of cancerous cells (IC50 = ~0.14 (compound 26) and 0.27 μM (compound 27). Moreover, compound 27 displayed an IC50 of ~5.9 μM to inhibit tubulin polymerization as it persuaded the degradation of Hsp70 and Akt protein through WB analysis. Different quinoline analogs have been reported as Hsp90 inhibitors with a cytotoxic function against cancerous cell lines. Accordingly, cytotoxic derivatives encompassing alcohol functional groups exhibited significant activity against MCF-7 cells. Among these evaluated compounds with anti-proliferative activity, compound 28 distinguished itself as the most effective analog in the degradation of Her2 protein, a client protein of Hsp90. The possible state of interaction between compound 28 and the N-terminal ATP binding pocket of Hsp90 was demonstrated by molecular modeling studies [109].
Liang et al. synthesized two new series of compounds of N-(5-chloro-2,4-dihydroxybenzoyl)-1,2,3,4-tetrahydroisoquinoline-3-carboxamides as Hsp90 inhibitors, which illustrated acceptable anti-proliferative activities against MDA-MB-231 and HeLa cell lines. Compound 29 unveiled strong cytotoxicity with inhibitory effects against the molecular proliferation of MDA-MB-231 (IC50 = ~0.98 µM) and HeLa (IC50 = ~1.74 µM). Moreover, the effective intracellular interaction of compound 29 with Hsp90α in 293T cells was confirmed through isothermal dose-response fingerprint curves. The induction activity of compound 29 in the degradation of CDK4, Her2, Cdc-2, and C-RAF Hsp90 client proteins was assessed by WB evaluation on MDA-MB-231 breast cancer cell lines [110].
Molecular docking and dynamic (MD) analyses on the complex of compound 29 and Hsp90 displayed its effective binding to Hsp90 through the interaction of its benzyl amino moiety with the residue Phe138, leading to the formation of a Π-stacking interaction [110]. Nepali et al. reported different fused quinoline-resorcinol compounds with powerful inhibitory activity against Hsp90. Through MD analysis of synthesized compounds in interactions with the Hsp90 chaperone protein receptor (Figure 3), compound 30 was determined as the ideal candidate. It interacted with the amino acid residues of the Hsp90 chaperone protein, resorcinol ring of compound 30, 1,3-dihydroxybenzene, link to chaperone function through amide bond formation with 1,3-dihydroxybenzene. In vitro studies indicated the effective cell growth inhibitory effect of compound 30, as one of the most active entities through in silico studies, against HCT-116 (colon), Hep3B (liver), and PC-3 (bone metastasis) cell lines [111].
Pharmaceutics 14 02220 g003
Figure 3. MD analysis of compound 30 in interaction with Hsp90. (A) compound 30 (blue) is anchored within the Hsp90 (gray) binding site. The three distinct sections of MPTG0G256 that are located in the S1, S2, and S3 sites, are colored as yellow, blue, and red, respectively. Interacting residues are shown as sticks and labeled as indicated. Hydrogen bonds are indicated by dotted green lines. (B) 2D representation of compound 30 docked in Hsp90. Green lines show regions of hydrophobic interactions. Interacting residues are labeled as indicated. Adapted from Ref. [111] with permission. Copyright 2019 Elsevier.
Relitti and co-workers synthesized various quinolone-based organic compounds as histone deacetylase 6 (HDAC6), wherein compounds 31 and 32 were introduced as the most promising active molecules against HDAC6. In addition, they displayed potent activity in cellular studies with development of inhibition against human cancer cell lines, HCT-116, and histiocytic lymphoma (U9347). It was an effective compound against tumor cells via apoptosis induction [112].

References

  1. Mahboubi-Rabbani, M.; Zarghi, A. Lipoxygenase Inhibitors as Cancer Chemopreventives: Discovery, Recent Developments and Future Perspectives. Curr. Med. Chem. 2021, 28, 1143–1175.
  2. Schopf, F.H.; Biebl, M.M.; Buchner, J. The Hsp90 chaperone machinery. Nat. Rev. Mol. Cell Biol. 2017, 18, 345–360.
  3. Mahalingam, D.; Swords, R.; Carew, J.S.; Nawrocki, S.T.; Bhalla, K.; Giles, F.J. Targeting HSP90 for cancer therapy. Br. J. Cancer 2009, 100, 1523–1529.
  4. Ischia, J.; So, A.I. The role of heat shock proteins in bladder cancer. Nat. Rev. Urol. 2013, 10, 386–395.
  5. Davenport, J.; Manjarrez, J.R.; Peterson, L.; Krumm, B.; Blagg, B.S.J.; Matts, R.L. Gambogic Acid, a Natural Product Inhibitor of Hsp90. J. Nat. Prod. 2011, 74, 1085–1092.
  6. Bhat, R.; Tummalapalli, S.R.; Rotella, D.P.J. Progress in the Discovery and Development of Heat Shock Protein 90 (Hsp90) Inhibitors: Miniperspective. Med. Chem. 2014, 57, 8718–8728.
  7. Jaeger, A.M.; Whitesell, L. Hsp90: Enabler of Cancer Adaptation. Annu. Rev. Cancer Biol. 2019, 3, 275–297.
  8. Gupta, S.D.; Bommaka, M.K.; Banerjee, A. Inhibiting protein-protein interactions of Hsp90 as a novel approach for targeting cancer. Eur. J. Med. Chem. 2019, 178, 48–63.
  9. Wang, L.; Zhang, Q.; You, Q. Targeting the HSP90–CDC37–kinase chaperone cycle: A promising therapeutic strategy for cancer. Med. Res. Rev. 2022, 42, 156–182.
  10. Li, L.; Chen, N.-N.; You, Q.-D.; Xu, X.-L. An updated patent review of anticancer Hsp90 inhibitors (2013–present). Expert Opin. Ther. Patents 2021, 31, 67–80.
  11. Niu, M.; Song, S.; Su, Z.; Wei, L.; Li, L.; Pu, W.; Zhao, C.; Ding, Y.; Wang, J.; Cao, W.; et al. Inhibition of heat shock protein (HSP) 90 reverses signal transducer and activator of transcription (STAT) 3-mediated muscle wasting in cancer cachexia mice. Br. J. Pharmacol. 2021, 178, 4485–4500.
  12. Jafari, A.; Rezaei-Tavirani, M.; Farhadihosseinabadi, B.; Taranejoo, S.; Zali, H. HSP90 and Co-chaperones: Impact on Tumor Progression and Prospects for Molecular-Targeted Cancer Therapy. Cancer Investig. 2020, 38, 310–328.
  13. Sanchez, J.; Carter, T.R.; Cohen, M.S.; Blagg, B.S.J. Old and New Approaches to Target the Hsp90 Chaperone. Curr. Cancer Drug Targets 2020, 20, 253–270.
  14. Trepel, J.; Mollapour, M.; Giaccone, G.; Neckers, L. Targeting the dynamic HSP90 complex in cancer. Nat. Rev. Cancer 2010, 10, 537–549.
  15. Nazaripour, E.; Mousazadeh, F.; Moghadam, M.D.; Najafi, K.; Borhani, F.; Sarani, M.; Ghasemi, M.; Rahdar, A.; Iravani, S.; Khatami, M. Biosynthesis of lead oxide and cerium oxide nanoparticles and their cytotoxic activities against colon cancer cell line. Inorg. Chem. Commun. 2021, 131, 108800.
  16. Iravani, S.; Varma, R.S. MXenes for Cancer Therapy and Diagnosis: Recent Advances and Current Challenges. ACS Biomater. Sci. Eng. 2021, 7, 1900–1913.
  17. Delfi, M.; Sartorius, R.; Ashrafizadeh, M.; Sharifi, E.; Zhang, Y.; De Berardinis, P.; Zarrabi, A.; Varma, R.S.; Tay, F.R.; Smith, B.R.; et al. Self-assembled peptide and protein nanostructures for anti-cancer therapy: Targeted delivery, stimuli-responsive devices and immunotherapy. Nano Today 2021, 38, 101119.
  18. Alavi, M.; Varma, R.S. Overview of Novel Strategies for the Delivery of Anthracyclines to Cancer Cells by Liposomal and Polymeric Nano Formulations. Int. J. Biol. Macromol. 2020, 164, 2197–2203.
  19. Makvandi, P.; Baghbantaraghdari, Z.; Zhou, W.; Zhang, Y.; Manchanda, R.; Agarwal, T.; Wu, A.; Maiti, T.K.; Varma, R.S.; Smith, B.R. Gum polysaccharide/nanometal hybrid biocomposites in cancer diagnosis and therapy. Biotechnol. Adv. 2021, 48, 107711.
  20. Hajipour, A.R.; Khorsandi, Z.; Mortazavi, M.; Farrokhpour, H. Green, efficient and large-scale synthesis of benzimidazoles, benzoxazoles and benzothiazoles derivatives using ligand-free cobalt-nanoparticles: As potential anti-estrogen breast cancer agents, and study of their interactions with estrogen receptor by molecular docking. RSC Adv. 2015, 5, 107822–107828.
  21. Khorsandi, Z.; Hajipour, A.R.; Sarfjoo, M.R.; Varma, R.S. A Pd/Cu-Free magnetic cobalt catalyst for C–N cross coupling reactions: Synthesis of abemaciclib and fedratinib. Green Chem. 2021, 23, 5222–5229.
  22. Khorsandi, Z.; Keshavarzipour, F.; Varma, R.S.; Hajipour, A.R.; Sadeghi-Aliabadi, H. Sustainable synthesis of potential antitumor new derivatives of Abemaciclib and Fedratinib via C-N cross coupling reactions using Pd/Cu-free Co-catalyst. Mol. Catal. 2021, 517, 112011.
  23. Whitesell, L.; Lindquist, S.L. HSP90 and the chaperoning of cancer. Nat. Rev. Cancer. 2005, 5, 761–772.
  24. Jego, G.; Hazoumé, A.; Seigneuric, R.; Garrido, C. Targeting heat shock proteins in cancer. Cancer Lett. 2013, 332, 275–285.
  25. Calderwood, S.K.; Khaleque, M.A.; Sawyer, D.B.; Ciocca, D.R. Heat Shock Proteins in Cancer: Chaperones of Tum Origenesis. J. Pet. Sci. Eng. 2006, 31, 164–172.
  26. Patel, H.J.; Patel, P.D.; Ochiana, S.O.; Yan, P.; Sun, W.; Patel, M.R.; Shah, S.K.; Tramentozzi, E.; Brooks, J.; Bolaender, A.J. Structure–Activity Relationship in a Purine-Scaffold Compound Series with Selectivity for the Endoplasmic Reticulum Hsp90 ParalogGrp94. Med. Chem. 2015, 58, 3922–3943.
  27. Johnson, J.L. Evolution and function of diverse Hsp90 homologs and cochaperone proteins. Biochim. Biophys. Acta Mol. Cell Res. 2012, 1823, 607–613.
  28. Csermely, P.; Miyata, Y.; Schnaider, T.; Yahara, I. Autophosphorylation of grp94 (Endoplasmin). J. Biol. Chem. 1995, 270, 6381–6388.
  29. Mishra, P.; Bolon, D.N. Designed Hsp90 Heterodimers Reveal an Asymmetric ATPase-Driven Mechanism In Vivo. Mol. Cell 2014, 53, 344–350.
  30. Meyer, P.; Prodromou, C.; Hu, B.; Vaughan, C.; Roe, S.M.; Panaretou, B.; Piper, P.W.; Pearl, L.H. Structural and Functional Analysis of the Middle Segment of Hsp90: Implications for ATP Hydrolysis and Client Protein and Cochaperone Interactions. Mol. Cell 2003, 11, 647–658.
  31. Gupta, S.D. Hsp90 Flexibility and Development of its Inhibitors for the Treatment of Cancer. Curr. Chem. Biol. 2018, 12, 53–64.
  32. Gupta, S.D. Novel Anti-Cancer Drugs Based on Hsp90 Inhibitory Mechanisms: A Recent Report. In Medicinal Chemistry with Pharma-Ceutical Product Development; Apple Academic Press: New York, NY, USA, 2019; pp. 57–104.
  33. Gupta, S.D.; Pan, C.H. Recent update on discovery and development of Hsp90 inhibitors as senolytic agents. Int. J. Biol. Macromol. 2020, 161, 1086–1098.
  34. Hanahan, D.; Weinberg, R.A. The Hallmarks of Cancer. Cell 2000, 100, 57–70.
  35. Hanahan, D.; Weinberg, R.A. Hallmarks of cancer: The next generation. Cell 2011, 144, 646–674.
  36. Vartholomaiou, E.; Echeverría, P.C.; Picard, D. Unusual Suspects in the Twilight Zone Between the Hsp90 Interactome and Carcinogenesis. Adv. Cancer Res. 2016, 129, 1–30.
  37. Hayat, U.; Elliott, G.T.; Olszanski, A.J.; Altieri, D.C. Feasibility and safety of targeting mitochondria for cancer therapy–preclinical characterization of gamitrinib, a first-in-class, mitochondriaL-targeted small molecule Hsp90 inhibitor. Cancer Biol. Ther. 2022, 23, 117–126.
  38. Biondini, M.; Kiepas, A.; El-Houjeiri, L.; Annis, M.G.; Hsu, B.E.; Fortier, A.-M.; Morin, G.; Martina, J.A.; Sirois, I.; Aguilar-Mahecha, A.; et al. HSP90 inhibitors induce GPNMB cell-surface expression by modulating lysosomal positioning and sensitize breast cancer cells to glembatumumab vedotin. Oncogene 2022, 41, 1701–1717.
  39. Epp-Ducharme, B.; Dunne, M.; Fan, L.; Evans, J.C.; Ahmed, L.; Bannigan, P.; Allen, C. Heat-activated nanomedicine formulation improves the anticancer potential of the HSP90 inhibitor luminespib in vitro. Sci. Rep. 2021, 11, 11103.
  40. Wu, Y.-W.; Chao, M.-W.; Tu, H.-J.; Chen, L.-C.; Hsu, K.-C.; Liou, J.-P.; Yang, C.-R.; Yen, S.-C.; HuangFu, W.-C.; Pan, S.-L. A novel dual HDAC and HSP90 inhibitor, MPT0G449, downregulates oncogenic pathways in human acute leukemia in vitro and in vivo. Oncogenesis 2021, 10, 39.
  41. Mshaik, R.; Simonet, J.; Georgievski, A.; Jamal, L.; Bechoua, S.; Ballerini, P.; Bellaye, P.-S.; Mlamla, Z.; de Barros, J.-P.P.; Geissler, A.; et al. HSP90 inhibitor NVP-BEP800 affects stability of SRC kinases and growth of T-cell and B-cell acute lymphoblastic leukemias. Blood Cancer J. 2021, 11, 61.
  42. Abdelmoaty, A.A.A.; Zhang, P.; Lin, W.; Fan, Y.-J.; Ye, S.-N.; Xu, J.-H. C0818, a novel curcumin derivative, induces ROS-dependent cytotoxicity in human hepatocellular carcinoma cells in vitro via disruption of Hsp90 function. Acta Pharmacol. Sin. 2022, 43, 446–456.
  43. Zhao, S.; Zhou, L.; Dicker, D.T.; Lev, A.; Zhang, S.; Ross, E.; El-Deiry, W.S. Anti-Cancer Efficacy Including Rb-Deficient Tumors and VHL-Independent HIF1α Proteasomal Destabilization by Dual Targeting of CDK1 or CDK4/6 and Hsp90. Sci. Rep. 2021, 11, 20871.
  44. Chen, X.-L.; Liu, P.; Zhu, W.-L.; Lou, L.-G. DCZ5248, a novel dual inhibitor of Hsp90 and autophagy, exerts antitumor activity against colon cancer. Acta Pharmacol. Sin. 2021, 42, 132–141.
  45. Cheng, C.-J.; Liu, K.-X.; Zhang, M.; Shen, F.-K.; Ye, L.-L.; Wu, W.-B.; Hou, X.-T.; Hao, E.-W.; Hou, Y.-Y.; Bai, G. Okicamelliaside targets the N-terminal chaperone pocket of HSP90 disrupts the chaperone protein interaction of HSP90-CDC37 and exerts antitumor activity. Acta Pharmacol. Sin. 2021, 43, 1046–1058.
  46. Konstantinopoulos, P.A.; Cheng, S.-C.; Supko, J.G.; Polak, M.; Wahner-Hendrickson, A.E.; Ivy, S.P.; Bowes, B.; Sawyer, H.; Basada, P.; Hayes, M.; et al. Combined PARP and HSP90 inhibition: Preclinical and Phase 1 evaluation in patients with advanced solid tumours. Br. J. Cancer 2021, 126, 1027–1036.
  47. Magwenyane, A.M.; Lawal, M.M.; Amoako, D.G.; Somboro, A.M.; Agoni, C.; Khan, R.B.; Mhlongo, N.N.; Kumalo, H.M. Exploring the inhibitory mechanism of resorcinylic isoxazole amine NVP-AUY922 towards the discovery of potential heat shock protein 90 (Hsp90) inhibitors. Sci. Afr. 2022, 15, e01107.
  48. Serwetnyk, M.A.; Blagg, S.J. The Disruption of Protein−Protein Interactions with Co-chaperones and Client Substrates as a Strategy Towards Hsp90 Inhibition. Acta. Pharm. Sin. B 2021, 11, 1446–1468.
  49. Roe, S.M.; Prodromou, C.; O’Brien, R.; Ladbury, J.E.; Piper, P.W.; Pearl, L.H. Structural Basis for Inhibition of the Hsp90 Molecular Chaperone by the Antitumor Antibiotics Radicicol and Geldanamycin. J. Med. Chem. 1999, 42, 260–266.
  50. Supko, J.G.; Hickman, R.L.; Grever, M.R.; Malspeis, L. Preclinical Pharmacologic Evaluation of Geldanamycin as an Antitumor Agent. Cancer Chemother. Pharmacol. 1995, 36, 305–315.
  51. Banerji, U.; O’Donnell, A.; Scurr, M.; Benson, C.; Hanwell, J.; Clark, S.; Raynaud, F.; Turner, A.; Walton, M.; Workman, P.; et al. Phase I Trial of the Heat Shock Protein 90 (Hsp90) Inhibitor 17-Allylamino 17-Demethoxygeldanamycin (17AAG). Pharmacokinetic (PK) Profile and Pharmacodynamic (PD) Endpoints. Proc. Am. Soc. Clin. Oncol. 2001, 20, 326.
  52. Egorin, M.J.; Zuhowski, E.G.; Rosen, D.M.; Sentz, D.L.; Covey, J.M.; Eiseman, J.L. Plasma pharmacokinetics and tissue distribution of 17-(allylamino)-17-demethoxygeldanamycin (NSC 330507) in CD2F1 mice1. Cancer Chemother. Pharmacol. 2001, 47, 291–302.
  53. Egorin, M.J.; Lagattuta, T.F.; Hamburger, D.R.; Covey, J.M.; White, K.D.; Musser, S.M.; Eiseman, J.L. Pharmacokinetics, tissue distribution, and metabolism of 17-(dimethylaminoethylamino)-17-demethoxygeldanamycin (NSC 707545) in CD2F1 mice and Fischer 344 rats. Cancer Chemother. Pharmacol. 2002, 49, 7–19.
  54. Munster, P.N.; Tong, L.; Schwartz, L.; Larson, S.; Kenneson, K.; De La Cruz, A.; Rosen, N.; Scher, H. Phase I Trial of 17(Allylamino)-17-demethoxygeldanamycin (17AAG) in Patients (Pts) with Advanced Solid Malignancies. Proc. Am. Soc. Clin. Oncol. 2001, 20, 83–91.
  55. Soga, S.; Sharma, S.V.; Shiotsu, Y.; Shimizu, M.; Tahara, H.; Yamaguchi, K.; Ikuina, Y.; Murakata, C.; Tamaoki, T.; Kurebayashi, J.; et al. Stereospecific antitumor activity of radicicol oxime derivatives. Cancer Chemother. Pharmacol. 2001, 48, 435–445.
  56. Johnson, V.A.; Singh, E.K.; Nazarova, L.A.; Alexander, L.D.; McAlpine, S.R. Macrocyclic inhibitors of hsp90. Curr. Top. Med. Chem. 2010, 10, 1380–1402.
  57. Porter, J.R.; Ge, J.; Lee, J.; Normant, E.; West, K. Ansamycin Inhibitors of Hsp90: Nature’s Prototype for Anti-chaperone Therapy. Curr. Top. Med. 2009, 9, 1386–1418.
  58. Tanida, S.; Hasegawa, T.; Higashide, E.; Macbecins, I.; Macbecins, I.I. New Antitumor Antibiotics. I. Producing Organism, Fermentation and Antimicrobial Activities. J. Antibiot. 1980, 33, 199–204.
  59. Tian, Z.-Q.; Liu, Y.; Zhang, D.; Wang, Z.; Dong, S.D.; Carreras, C.W.; Zhou, Y.; Rastelli, G.; Santi, D.V.; Myles, D.C. Synthesis and biological activities of novel 17-aminogeldanamycin derivatives. Bioorg. Med. Chem. 2004, 12, 5317–5329.
  60. Wagner, A.J.; Chugh, R.; Rosen, L.S.; Morgan, J.A.; George, S.; Gordon, M.; Dunbar, J.; Normant, E.; Grayzel, D.; Demetri, G.D. A Phase I Study of the HSP90 Inhibitor Retaspimycin Hydrochloride (IPI-504) in Patients with Gastrointestinal Stromal Tumors or Soft-Tissue Sarcomas. Clin. Cancer Res. 2013, 19, 6020–6029.
  61. Floris, G.; Debiec-Rychter, M.; Wozniak, A.; Stefan, C.; Normant, E.; Faa, G.; Machiels, K.; Vanleeuw, U.; Sciot, R.; Schöffski, P. The Heat Shock Protein 90 Inhibitor IPI-504 Induces KIT Degradation, Tumor Shrinkage, and Cell Proliferation Arrest in Xenograft Models of Gastrointestinal Stromal Tumors. Mol. Cancer Ther. 2011, 10, 1897–1908.
  62. Floris, G.; Sciot, R.; Wozniak, A.; Van Looy, T.; Wellens, J.; Faa, G.; Normant, E.; Debiec-Rychter, M.; Schöffski, P. The Novel Hsp90 inhibitor, IPI-493, is Highly Effective in Human Gastrostrointestinal Stromal Tumor Xenografts Carrying Heterogeneous KIT Mutations. Clin. Cancer Res. 2011, 17, 5604–5614.
  63. Whitesell, L.; Mimnaugh, E.G.; De Costa, B.; Myers, C.E.; Neckers, L.M. Inhibition of heat shock protein HSP90-pp60v-src heteroprotein complex formation by benzoquinone ansamycins: Essential role for stress proteins in oncogenic transformation. Proc. Natl. Acad. Sci. USA 1994, 91, 8324–8328.
  64. Stebbins, C.E.; Russo, A.A.; Schneider, C.; Rosen, N.; Hartl, F.; Pavletich, N.P. Crystal Structure of an Hsp90–Geldanamycin Complex: Targeting of a Protein Chaperone by an Antitumor Agent. Cell 1997, 89, 239–250.
  65. Soga, S.; Shiotsu, Y.; Akinaga, S.; Sharma, S. Development of Radicicol Analogues. Curr. Cancer Drug Targets 2003, 3, 359–369.
  66. Miyata, Y. Hsp90 Inhibitor Geldanamycin and Its Derivatives as Novel Cancer Chemotherapeutic Agents. Curr. Pharm. Des. 2005, 11, 1131–1138.
  67. Chiosis, G.; Lucas, B.; Huezo, H.; Solit, D.; Basso, A.; Rosen, N. Development of Purine-Scaffold Small Molecule Inhibitors of Hsp90. Curr. Cancer Drug Targets 2003, 3, 371–376.
  68. Conejo-García, A.; García-Rubiño, M.E.; Marchal, J.A.; Núñez, M.C.; Ramírez, A.; Cimino, S.; García, M.; Aránega, A.; Gallo, M.A.; Campos, J.M. Synthesis and anticancer activity of (RS)-9-(2,3-dihydro-1,4-benzoxaheteroin-2-ylmethyl)-9H-purines. Eur. J. Med. Chem. 2011, 46, 3795–3801.
  69. Pelliccia, S.; Amato, J.; Capasso, D.; Di Gaetano, S.; Massarotti, A.; Piccolo, M.; Irace, C.; Tron, G.C.; Pagano, B.; Randazzo, A.J. Bio-Inspired Dual-Selective BCL-2/c-MYC G-Quadruplex Binders: Design, Synthesis, and Anticancer Activity of Drug-like Imidazo purine Derivatives. Med. Chem. 2019, 63, 2035–2050.
  70. Ashour, F.A.; Rida, S.M.; El-Hawash, S.A.; ElSemary, M.M.; Badr, M.H. Synthesis, Anticancer, Anti-HIV-1, and Antimicrobial Activity of Some Tricyclic Triazino and Triazolo purine Derivatives. Cancer Causes Control 2012, 21, 1107–1119.
  71. Kinali-Demirci, S.; İdil, Ö.; Dişli, A. Synthesis of Some Novel Purine Derivatives Incorporating Tetrazole Ring and Investigation of their Antimicrobial Activity and DNA Interactions. Cancer Cell Int. J. Mol. Histol. 2015, 24, 1218–1225.
  72. Abdallah, A.E.; Elgemeie, G.H. Development; Therapy, Design, Synthesis, Docking, and Antimicrobial Evaluation of Some Novel Pyrazolo Pyrimidines and their Corresponding Cycloalkane Ring-fused Derivatives as Purine Analogs. Drug Des. Devel. Ther. 2018, 12, 1785–1798.
  73. Rosemeyer, H. The Chemodiversity of Purine as a Constituent of Natural Products. Chem. Biodivers. 2004, 1, 361–401.
  74. Kaneko, K.; Aoyagi, Y.; Fukuuchi, T.; Inazawa, K.; Yamaoka, N. Total Purine and Purine Base Content of Common Foodstuffs for Facilitating Nutritional Therapy for Gout and Hyperuricemia. Biol. Pharm. Bull. 2014, 37, 709–721.
  75. Yin, J.; Ren, W.; Huang, X.; Deng, J.; Li, T.; Yin, Y. Potential Mechanisms Connecting Purine Metabolism and Cancer Therapy. Front. Immunol. 2018, 9, 1697.
  76. Chiosis, G.; Timaul, M.N.; Lucas, B.; Munster, P.N.; Zheng, F.F.; Sepp-Lorenzino, L.; Rosen, N. A small molecule designed to bind to the adenine nucleotide pocket of Hsp90 causes Her2 degradation and the growth arrest and differentiation of breast cancer cells. Chem. Biol. 2001, 8, 289–299.
  77. Bao, R.; Lai, C.-J.; Qu, H.; Wang, D.; Yin, L.; Zifcak, B.; Atoyan, R.; Wang, J.; Samson, M.; Forrester, J.; et al. CUDC-305, a Novel Synthetic HSP90 Inhibitor with Unique Pharmacologic Properties for Cancer Therapy. Clin. Cancer Res. 2009, 15, 4046–4057.
  78. Zhang, H.; Neely, L.; Lundgren, K.; Yang, Y.-C.; Lough, R.; Timple, N.; Burrows, F. BIIB021, a synthetic HSP90 inhibitor, has broad application against tumors with acquired multidrug resistance. Int. J. Cancer 2010, 126, 1226–1234.
  79. Yin, X.; Zhang, H.; Lundgren, K.; Wilson, L.; Burrows, F.; Shores, C.G. BIIB021, a novel HSP90 inhibitor, sensitizes head and neck squamous cell carcinoma to radiotherapy. Int. J. Cancer 2010, 126, 1216–1225.
  80. Chaurasiya, A.; Wahan, S.K.; Sahu, C.; Chawla, P.A. An insight into the rational design of recent purine-based scaffolds in targeting various cancer pathways. J. Mol. Struct. 2022, 134308.
  81. Wang, X.-T.; Bao, C.-H.; Jia, Y.-B.; Wang, N.; Ma, W.; Liu, F.; Wang, C.; Wang, J.-B.; Song, Q.-X.; Cheng, Y.-F. BIIB021, a novel Hsp90 inhibitor, sensitizes esophageal squamous cell carcinoma to radiation. Biochem. Biophys. Res. Commun. 2014, 452, 945–950.
  82. ElFiky, A.; Saif, M.W.; Beeram, M.; Brien, S.O.; Lammanna, N.; Castro, J.E.; Woodworth, J.; Perea, R.; Storgard, C.; Von Hoff, D.D. BIIB021, an oral, synthetic non-ansamycin Hsp90 inhibitor: Phase I experience. J. Clin. Oncol. 2008, 26, 2503.
  83. Dickson, M.A.; Okuno, S.H.; Keohan, M.L.; Maki, R.G.; D’Adamo, D.R.; Akhurst, T.J.; Antonescu, C.R.; Schwartz, G.K. Phase II study of the HSP90-inhibitor BIIB021 in gastrointestinal stromal tumors. Ann. Oncol. 2013, 24, 252–257.
  84. Emami, S.; Dadashpour, S. Current developments of coumarin-based anti-cancer agents in medicinal chemistry. Eur. J. Med. Chem. 2015, 102, 611–630.
  85. Zhang, L.; Xu, Z. Coumarin-containing hybrids and their anticancer activities. Eur. J. Med. Chem. 2019, 181, 111587.
  86. Al-Warhi, T.; Sabt, A.; Elkaeed, E.B.; Eldehna, W.M. Recent advancements of coumarin-based anticancer agents: An up-to-date review. Bioorg. Chem. 2020, 103, 104163.
  87. Song, X.; Fan, J.; Liu, L.; Liu, X.; Gao, F. Coumarin derivatives with anticancer activities: An update. Arch. Pharm. 2020, 353, 2000025.
  88. Qin, H.-L.; Zhang, Z.-W.; Ravindar, L.; Rakesh, K. Antibacterial activities with the structure-activity relationship of coumarin derivatives. Eur. J. Med. Chem. 2020, 207, 112832.
  89. Keshavarzipour, F.; Tavakol, H. The synthesis of coumarin derivatives using choline chloride/zinc chloride as a deep eutectic solvent. J. Iran. Chem. Soc. 2016, 13, 149–153.
  90. Ahmed, E.Y.; Elserwy, W.S.; El-Mansy, M.F.; Serry, A.M.; Salem, A.M.; Abdou, A.M.; Abdelrahman, B.A.; Elsayed, K.H.; Elaziz, M.R.A. Angiokinase inhibition of VEGFR-2, PDGFR and FGFR and cell growth inhibition in lung cancer: Design, synthesis, biological evaluation and molecular docking of novel azaheterocyclic coumarin derivatives. Bioorg. Med. Chem. Lett. 2021, 48, 128258.
  91. Burlison, J.A.; Neckers, L.; Smith, A.B.; Maxwell, A.A.; Blagg, B.S.J. Novobiocin: Redesigning a DNA Gyrase Inhibitor for Selective Inhibition of Hsp90. J. Am. Chem. Soc. 2006, 128, 15529–15536.
  92. Shelton, S.N.; Shawgo, M.E.; Matthews, S.B.; Lu, Y.; Donnelly, A.C.; Szabla, K.; Tanol, M.; Vielhauer, G.A.; Rajewski, R.A.; Matts, R.L.; et al. KU135, a Novel Novobiocin-Derived C-Terminal Inhibitor of the 90-kDa Heat Shock Protein, Exerts Potent Antiproliferative Effects in Human Leukemic Cells. Mol. Pharmacol. 2009, 76, 1314–1322.
  93. Garg, G.; Zhao, H.; Blagg, B.S.J. Design, Synthesis, and Biological Evaluation of Ring-Constrained Novobiocin Analogues as Hsp90 C-Terminal Inhibitors. ACS Med. Chem. Lett. 2015, 6, 204–209.
  94. Wei, Q.; Ning, J.-Y.; Dai, X.; Gao, Y.-D.; Su, L.; Zhao, B.-X.; Miao, J.-Y. Discovery of novel HSP90 inhibitors that induced apoptosis and impaired autophagic flux in A549 lung cancer cells. Eur. J. Med. Chem. 2018, 145, 551–558.
  95. Kouznetsov, V.V.; Méndez, L.Y.V.; Galvis, C.E.P.; Villamizar, M.C.O. The direct C–H alkenylation of quinoline N-oxides as a suitable strategy for the synthesis of promising antiparasitic drugs. New J. Chem. 2020, 44, 12–19.
  96. Keshavarzipour, F.; Tavakol, H. Zinc Cation Supported on Carrageenan Magnetic Nanoparticles: A Novel, Green and Efficient Catalytic System for One-pot Three-Component Synthesis of Quinoline Derivatives. Appl. Organomet. Chem. 2017, 31, 3682–3692.
  97. Insuasty, D.; García, S.; Abonia, R.; Insuasty, B.; Quiroga, J.; Nogueras, M.; Laali, K.K. Design, Synthesis, and Molecular Docking Study of Novel Quinoline-Based Bis-Chalcones as Potential Antitumor Agents. Arch. Pharm. 2021, 354, 2100094–2100103.
  98. Jin, G.; Li, Z.; Xiao, F.; Qi, X.; Sun, X. Optimization of activity localization of quinoline derivatives: Design, synthesis, and dual evaluation of biological activity for potential antitumor and antibacterial agents. Bioorg. Chem. 2020, 99, 103837.
  99. Mishra, S.; Salahuddin, R.K.; Majumder, A.; Kumar, A.; Singh, C.; Tiglani, D. Updates on Synthesis and Biological Activities of Quinoline Derivatives: A Review. Int. J. Pharm. Sci. Rev. Res. 2021, 13, 3941–3960.
  100. Goyal, S.; Binnington, B.; McCarthy, S.D.; Desmaële, D.; Férrié, L.; Figadère, B.; Loiseau, P.M.; Branch, D.R. Inhibition of in vitro Ebola infection by anti-parasitic quinoline derivatives. F1000Research 2020, 9, 268.
  101. Verma, C.; Quraishi, M.; Ebenso, E.E. Quinoline and its derivatives as corrosion inhibitors: A review. Surfaces Interfaces 2020, 21, 100634.
  102. Kayamba, F.; Malimabe, T.; Ademola, I.K.; Pooe, O.J.; Kushwaha, N.D.; Mahlalela, M.; van Zyl, R.L.; Gordon, M.; Mudau, P.T.; Zininga, T.; et al. Design and synthesis of quinoline-pyrimidine inspired hybrids as potential plasmodial inhibitors. Eur. J. Med. Chem. 2021, 217, 113330.
  103. Rao, K.V.; Cullen, W.P. Streptonigrin, an Antitumor Substance. I. Isolation and Characterization. Antibiot. Annu. 1959, 7, 950–953.
  104. Chirigos, M.A.; Pearson, J.W.; Papas, T.S.; Woods, W.A.; Wood, H.B., Jr.; Spahn, G. Effect of Three Strains of BeG Against a Murine Leukemia After Drug Therapy. Cancer Chemother. Rep. 1973, 57, 305–309.
  105. Balitz, D.M.; Bush, J.A.; Bradner, W.T.; Doyle, T.W.; O’Herron, F.A.; Nettleton, D.E. Isolation of lavendamycin. A new antibiotic from Streptomyces lavendulae. J. Antibiot. 1982, 35, 259–265.
  106. Ganesh, T.; Min, J.; Thepchatri, P.; Du, Y.; Li, L.; Lewis, I.; Wilson, L.; Fu, H.; Chiosis, G.; Dingledine, R.; et al. Discovery of aminoquinolines as a new class of potent inhibitors of heat shock protein 90 (Hsp90): Synthesis, biology, and molecular modeling. Bioorg. Med. Chem. 2008, 16, 6903–6910.
  107. Audisio, D.; Messaoudi, S.; Cegielkowski, L.; Peyrat, J.-F.; Brion, J.-D.; Methy-Gonnot, D.; Radanyi, C.; Renoir, J.-M.; Alami, M. Discovery and Biological Activity of 6BrCaQ as an Inhibitor of the Hsp90 Protein Folding Machinery. Chem. Med. Chem. 2011, 6, 804–815.
  108. Nepali, K.; Kumar, S.; Huang, H.-L.; Kuo, F.-C.; Lee, C.-H.; Kuo, C.-C.; Yeh, T.-K.; Li, Y.-H.; Chang, J.-Y.; Liou, J.-P.; et al. 2-Aroylquinoline-5,8-diones as potent anticancer agents displaying tubulin and heat shock protein 90 (HSP90) inhibition. Org. Biomol. Chem. 2015, 14, 716–723.
  109. Malayeri, S.O.; Abnous, K.; Arab, A.; Akaberi, M.; Mehri, S.; Zarghi, A.; Ghodsi, R. Design, Synthesis and Biological Evaluation of 7-(Aryl)-2,3-dihydro- dioxino Quinoline Derivatives as Potential Hsp90 Inhibitors and Anticancer Agents. Bioorg. Med. Chem. 2017, 25, 1294–1302.
  110. Liang, C.; Hao, H.; Wu, X.; Li, Z.; Zhu, J.; Lu, C.; Shen, Y. Design and synthesis of N-(5-chloro-2,4-dihydroxybenzoyl)-(R)-1,2,3,4-tetrahydroisoquinoline-3-carboxamides as novel Hsp90 inhibitors. Eur. J. Med. Chem. 2016, 121, 272–282.
  111. Nepali, K.; Lin, M.-H.; Chao, M.-W.; Peng, S.-J.; Hsu, K.-C.; Lin, T.E.; Chen, M.-C.; Lai, M.-J.; Pan, S.-L.; Liou, J.-P. Amide-tethered quinoline-resorcinol conjugates as a new class of HSP90 inhibitors suppressing the growth of prostate cancer cells. Bioorg. Chem. 2019, 91, 103119.
  112. Relitti, N.; Saraswati, A.P.; Chemi, G.; Brindisi, M.; Brogi, S.; Herp, D.; Schmidtkunz, K.; Saccoccia, F.; Ruberti, G.; Ulivieri, C.; et al. Novel quinolone-based potent and selective HDAC6 inhibitors: Synthesis, molecular modeling studies and biological investigation. Eur. J. Med. Chem. 2021, 212, 112998.
More
© Text is available under the terms and conditions of the Creative Commons Attribution (CC BY) license; additional terms may apply. By using this site, you agree to the Terms and Conditions and Privacy Policy.
Upload a video for this entry
Information
Subjects: Medicine, Research & Experimental
Contributors MDPI registered users' name will be linked to their SciProfiles pages. To register with us, please refer to https://encyclopedia.pub/register :
Mina Ardestani
,
Zahra Khorsandi
,
Fariba Keshavarzipour
,
Siavash Iravani
,
Hojjat Sadeghi-Aliabadi
,
Rajender S. Varma
View Times: 425
Revisions: 2 times (View History)
Update Date: 07 Nov 2022
Table of Contents
    1000/1000
    Hot Most Recent
    ScholarVision Creations
    Feedback